Meister Keith A. sold $57.2M of ILMN (indirect holdings)

Meister Keith A. sold 263,560 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $217.03 ($213.20–$221.55, $57.20M total) across 12 trades over 2026-09-02 to 2026-09-04.

Original reporting
SEC EDGAR · Meister Keith A.
Published Sep 4, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
high confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishMed
01

Why it matters

The $57.2M sale is the first public disclosure of this insider activity, providing new data for traders.

02

Market read

First‑report insider sale of significant size; may influence short‑term price action and sentiment in the biotech sector.

03

What to watch

The sale was executed via multiple small trades and may reflect personal tax planning rather than company outlook.

Relevance 8/10Novelty 8/10Timing: post‑market filing on 2026‑09‑04

Background

SEC Form 4 filing discloses insider transactions; director sales are monitored for signals about company health.

Company-level read

Ticker impact

$ILMNBearishHigh confidence
Context

Director Meister Keith A. sold 263,560 shares worth $57.2M, reducing his stake to 770,350 shares.

Expected impact

Short-term price dip expected as market digests the $57M sale.

Evidence & confidence

The sale size is material for a mid‑cap biotech and is disclosed for the first time via a Form 4 filing.

Market effects

May raise concerns for other diagnostics and genomics firms as insider confidence is questioned.

Limited to U.S. biotech sector; no broader regional effect.

Minimal global impact beyond Illumina shareholders.

Counterpoint

Insider sales can be routine liquidity events; the market may overreact to the headline.

Key entities

  • Illumina, Inc.

    US‑listed genomics and diagnostics firm (ticker ILMN).

  • Meister Keith A.

    Director of Illumina who executed the share sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.